Enanta Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 145

Market Cap: $275.6M

Website

Introduction: Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Clinical Trials

A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants

Phase 1

Recruiting

Conditions: RSV Infection
Drug Drug Interaction

Interventions: Drug: EDP-323
Drug: Midazolam
Drug: Caffeine
Drug: Rosuvastatin

First Posted Date: 2025-04-08

Last Posted Date: 2025-04-08

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 24

Registration Number: NCT06917508

Locations: 🇺🇸
ICON, plc, San Antonio, Texas, United States

A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.

Phase 1

Recruiting

Conditions: RSV Infection
Drug Drug Interaction (DDI)

Interventions: Drug: EDP-323
Drug: Itraconazole
Drug: carbamazepine
Drug: Quinidine
Drug: fluconazole

First Posted Date: 2025-02-26

Last Posted Date: 2025-02-26

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 48

Registration Number: NCT06847464

Locations: 🇺🇸
ICON, plc, San Antonio, Texas, United States

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Phase 1

Recruiting

Conditions: RSV Infection
QTc Interval

Interventions: Drug: zelicapavir (therapeutic dose)
Drug: zelicapavir (supratherapeutic dose)
Drug: Placebo
Drug: moxifloxacin

First Posted Date: 2024-09-19

Last Posted Date: 2024-10-24

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 72

Registration Number: NCT06601192

Locations: 🇺🇸
ICON Early Phase, LLC, San Antonio, Texas, United States
🇺🇸
ICON, Lenexa, Kansas, United States

A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model

Phase 2

Completed

Conditions: RSV Infection

Interventions: Drug: EDP-323 Dose Regimen 1
Drug: EDP-323 Dose Regimen 2
Drug: Placebo

First Posted Date: 2023-12-14

Last Posted Date: 2024-10-16

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 142

Registration Number: NCT06170242

Locations: 🇬🇧
hVIVO Services Limited, London, United Kingdom

A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: EDP-235

First Posted Date: 2022-11-15

Last Posted Date: 2024-08-19

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 231

Registration Number: NCT05616728

Locations: 🇷🇴
County Emergency Hospital, Cluj-Napoca, Cluj, Romania
🇺🇸
D&H National Research Centers, Miami, Florida, United States
🇺🇸
USPA Advance Concept Medical Research Group. LLC, Miami, Florida, United States

and more 20 locations

Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastatin in Healthy Subjects

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: EDP-235
Drug: Midazolam
Drug: Rosuvastatin
Drug: Caffeine

First Posted Date: 2022-10-26

Last Posted Date: 2023-04-27

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 24

Registration Number: NCT05594615

Locations: 🇺🇸
ICON, plc., Salt Lake City, Utah, United States

Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Quinidine in Healthy Subjects.

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: EDP-235
Drug: Carbamazepine
Drug: Itraconazole
Drug: Quinidine

First Posted Date: 2022-10-26

Last Posted Date: 2023-04-27

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 36

Registration Number: NCT05594602

Locations: 🇺🇸
ICON, plc., Lenexa, Kansas, United States

A Study of EDP-323 in Healthy Subjects

Phase 1

Completed

Conditions: RSV Infection

Interventions: Drug: Placebo
Drug: EDP-323

First Posted Date: 2022-10-20

Last Posted Date: 2023-09-01

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 82

Registration Number: NCT05587478

Locations: 🇺🇸
ICON, plc., Lenexa, Kansas, United States

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

Phase 2

Recruiting

Conditions: RSV Infection

Interventions: Drug: Placebo
Drug: EDP-938

First Posted Date: 2022-10-06

Last Posted Date: 2025-04-25

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 180

Registration Number: NCT05568706

Locations: 🇺🇸
Voyage Medical, Tempe, Arizona, United States
🇦🇷
Instituto de Medicina Respiratoria, IMeR, Córdoba, Argentina
🇦🇷
Instituto Del Buen Aire, Santa Fe, Argentina

and more 162 locations

A Study of EDP-235 in Healthy Subjects

Phase 1

Completed

Conditions: SARS CoV 2 Infection

Interventions: Drug: Placebo
Drug: EDP-235

First Posted Date: 2022-02-18

Last Posted Date: 2022-08-19

Lead Sponsor: Enanta Pharmaceuticals, Inc

Target Recruit Count: 72

Registration Number: NCT05246878

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States

Home Terms & Conditions Privacy Policy